PT - JOURNAL ARTICLE AU - Majumdar, Debatosh AU - Jung, Kyung-Ho AU - Zhang, Hongzheng AU - Nannapaneni, Sreenivas AU - Wang, Xu AU - Amin, A.R.M. Ruhul AU - Chen, Zhengjia AU - Chen, Zhuo (G). AU - Shin, Dong M. TI - Luteolin Nanoparticle in Chemoprevention: <em>In Vitro</em> and <em>In Vivo</em> Anticancer Activity AID - 10.1158/1940-6207.CAPR-13-0230 DP - 2014 Jan 01 TA - Cancer Prevention Research PG - 65--73 VI - 7 IP - 1 4099 - http://cancerpreventionresearch.aacrjournals.org/content/7/1/65.short 4100 - http://cancerpreventionresearch.aacrjournals.org/content/7/1/65.full SO - Cancer Prev Res (Phila)2014 Jan 01; 7 AB - Cancer prevention (chemoprevention) by using naturally occurring dietary agents has gained immense interest because of the broad safety window of these compounds. However, many of these compounds are hydrophobic and poorly soluble in water. They frequently display low bioavailability, poor systemic delivery, and low efficacy. To circumvent this problem, we explored a novel approach toward chemoprevention using nanotechnology to deliver luteolin, a natural compound present in green vegetables. We formulated water-soluble polymer-encapsulated Nano-Luteolin from hydrophobic luteolin, and studied its anticancer activity against lung cancer and head and neck cancer. In vitro studies demonstrated that, like luteolin, Nano-Luteolin inhibited the growth of lung cancer cells (H292 cell line) and squamous cell carcinoma of head and neck (SCCHN) cells (Tu212 cell line). In Tu212 cells, the IC50 value of Nano-Luteolin was 4.13 μmol/L, and that of luteolin was 6.96 μmol/L. In H292 cells, the IC50 of luteolin was 15.56 μmol/L, and Nano-Luteolin was 14.96 μmol/L. In vivo studies using a tumor xenograft mouse model demonstrated that Nano-Luteolin has a significant inhibitory effect on the tumor growth of SCCHN in comparison to luteolin. Our results suggest that nanoparticle delivery of naturally occurring dietary agents like luteolin has many advantages and may have potential application in chemoprevention in clinical settings. Cancer Prev Res; 7(1); 65–73. ©2013 AACR.